YOKNEAM, Israel and IRVINE, Calif., Oct. 19 /PRNewswire/ -- Syneron Medical Ltd. (Nasdaq: ELOS), http://www.syneron.com, a leading medical aesthetic device innovator, is announcing their new VelaBABE™ (Vela Body After Baby Enthusiast!) promotion for women who want to reclaim their pre-baby body – with help from VelaShape™. Introduced in 2007, VelaShape is the first FDA-cleared device for cellulite and circumference reduction, to tighten and smooth trouble spots that diet and exercise can't quite fix. Women who enter the VelaBABE promotion will have the opportunity to experience a free VelaShape treatment.
Pregnancy is a beautiful, unforgettable experience, but during the nine months of pregnancy the body undergoes dramatic changes. For most women, bouncing back to a pre-baby body can be difficult. In a national survey of 500 moms conducted by M/A/R/C Research, nearly every mom agreed that their pregnancy had changed their body. According to those surveyed, the stomach and thighs were identified as major problem areas for getting back into shape after giving birth (by 85 percent and 47 percent, respectively).
"Moms are constantly juggling extra responsibilities and often put their own health on the back burner. But even for women exercising regularly and eating well, it can be tough to tone certain areas post-pregnancy," said Lori Brightman, MD, Laser & Skin Surgery Center of New York. "VelaShape is an easy, effective way that my patients can get rid of cellulite and tone up. Most of my patients find that VelaShape helps boost their confidence, too, so they can spend more time enjoying motherhood instead of worrying about their thighs or tummy. The VelaBABE promotion offers a great opportunity for women across the country to see what VelaShape can do for them!"
Over 3.5 million women have already experienced VelaShape, many of whom became VelaBABEs and restored their body and reclaimed their confidence. For more information about VelaShape, become a fan of VelaBABE on www.VelaShape.com and learn more about the special promotion!
About Syneron Medical Ltd.
Syneron Medical Ltd. – a company devoted to technology, science and results – is the leading global aesthetic device company with a comprehensive product portfolio and a global distribution footprint. The Company's technology enables physicians to provide advanced solutions for a broad range of medical-aesthetic applications including body contouring, hair removal, wrinkle reduction, rejuvenation of the skin's appearance through the treatment of superficial benign vascular and pigmented lesions, and the treatment of acne, leg veins and cellulite. The Company sells its products under two distinct brands, Syneron and Candela. With its innovative approach to aesthetic treatments, Syneron has now entered into one of the largest in-demand applications, skin lightening. Founded in 2000, the corporate, R&D, and manufacturing headquarters for Syneron Medical Ltd. are located in Israel. Syneron also has R&D and manufacturing operations in the US. The company markets and services and supports its products in 86 countries. It has offices in North America, France, Germany, Italy, Portugal, Spain, UK, Australia, China, Japan, and Hong Kong and distributors worldwide.
SAFE HARBOR FOR FORWARD-LOOKING STATEMENTS
Any statements contained in this document regarding future expectations, beliefs, goals, plans or prospects constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Further, any statements that are not statements of historical fact (including statements containing "believes," "anticipates," "plans," "expects," "may," "will," "would," "intends," "estimates" and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including the risk that the businesses of Syneron and Candela may not be integrated successfully; the risk that the merger transaction with Candela may involve unexpected costs or unexpected liabilities; the risk that synergies from the merger transaction may not be fully realized or may take longer to realize than expected; the risk that disruptions from the merger transaction make it more difficult to maintain relationships with customers, employees, or suppliers; as well as the risks set forth in Syneron Medical Ltd.'s most recent Annual Report on Form 20-F, and the other factors described in the filings that Syneron Medical Ltd. makes with the SEC from time to time. If one or more of these factors materialize, or if any underlying assumptions prove incorrect, Syneron Medical Ltd.'s actual results, performance or achievements may vary materially from any future results, performance or achievements expressed or implied by these forward-looking statements.
In addition, the statements in this document reflect the expectations and beliefs of Syneron Medical Ltd. as of the date of this document. Syneron Medical Ltd. anticipates that subsequent events and developments will cause its expectations and beliefs to change. However, while Syneron Medical Ltd. may elect to update these forward-looking statements publicly in the future, it specifically disclaims any obligation to do so. The forward-looking statements of Syneron Medical Ltd. do not reflect the potential impact of any future dispositions or strategic transactions that may be undertaken. These forward-looking statements should not be relied upon as representing Syneron Medical Ltd.'s views as of any date after the date of this document.
SOURCE Syneron Medical Ltd.